The article discusses the risk factors and ethical problems associated with ignoring racial and ethnic minorities in clinical trials. Topics include concerns regarding whether treatments will work in all populations or what side effects might emerge in various groups if minorities are not included in trials, the National Institutes of Health Revitalization Act to include more women and people of color in research, and the tendency for minorities to not have access to specialty care centers that recruit subjects for trials.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados